ArticleFrontiers in psychology2026
The association between fear of disease progression and financial toxicity in patients with chronic osteomyelitis: a cross-sectional study.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic osteomyelitis (COM) is a persistent and refractory bone infection associated with substantial physical, psychological, and economic burdens. However, evidence linking financial toxicity (FT) to fear of disease progression (FoP) in patients with COM remains scarce. In this cross-sectional study, we recruited 214 patients with COM from a tertiary hospital in Nanchong, China, between June 2024 and June 2025. Participants completed electronic questionnaires assessing demographic/clinical characteristics, FoP (Fear of Progression Questionnaire-Short Form), and FT (Comprehensive Score for Financial Toxicity). The mean FoP score was 38.31 ± 7.18. Notably, 77.1% (165/214) of patients exhibited clinically relevant levels of FoP (score ≥ 34), indicating a high prevalence of psychological distress. Spearman's rank correlation was observed between FoP and COST scores (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.